Cresco Labs Inc. cultivates, manufactures, and sells cannabis products in the U.S. Key strengths include a solid gross margin of 50.2% and a current ratio of 1.78, indicating good liquidity. However, concerns arise from a relatively low return on equity (4.7%) and a high debt-to-equity ratio (1.65), suggesting potential leverage risks. Despite healthy margins, the stock's low price of $0.84 raises questions about market valuation, indicating investor caution in the sector.
Loading financial metrics...
Company posted a loss of $-100.9M over the last year, representing 15.5% of revenue.
Debt of $592.0M is 9.2x the company's cash position of $64.1M.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)